InvestorsHub Logo
Followers 7
Posts 637
Boards Moderated 0
Alias Born 07/13/2003

Re: Theo post# 15051

Wednesday, 06/16/2004 12:07:49 PM

Wednesday, June 16, 2004 12:07:49 PM

Post# of 82595
Thanks Theo...tho it looks like Dutton clearly disclosed that they received payment by DNAP in their PR announcement:

J.M. Dutton & Associates Announces Investment Opinion: DNAPrint genomics Speculative Buy Rating in Initiating Coverage by Dutton & Associates - Tuesday June 8, 10:30 am ET

EL DORADO HILLS, Calif.--(BUSINESS WIRE)--June 8, 2004--J.M. Dutton & Associates initiates coverage of DNAPrint genomics (OTCBB:DNAP - News) with a Speculative Buy rating. The 22-page report by J.M. Dutton senior analyst Sherry Grisewood, CFA is available at www.jmdutton.com as well as from First Call, Bloomberg, Zacks, Multex, and other leading financial portals.

The cost of enrollment in our one-year continuing research program is US $28,000 prepaid before commencement of our research activities. We received $28,000 from the Company for coverage for the year, and do not accept payment of our fees in company stock. Our principals and analysts are prohibited from owning or trading in securities of covered companies.
-----

Curious why the SEC doesn't feel that this was disclosure enough and why DNAP was listed along with the others...?

God Bless and take care,

Robert